

Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*
KINTOR PHARMACEUTICAL LIMITED
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 9939)

**(1) CHANGE IN EXECUTIVE DIRECTORS;
(2) CHANGE IN CHIEF FINANCIAL OFFICER; AND
(3) CHANGE IN JOINT COMPANY SECRETARY**

The Board announces that, with effect from 14 April 2023,

- (1) Dr. Qun LU and Dr. Xiang NI, who are respectively the existing CTO and CMO of the Company, have been appointed as executive Directors; and
- (2) Mr. Ming Ming CHEUNG has been appointed as the CFO.

Meanwhile, Ms. Yan LU has resigned as an executive Director, the CFO and a joint company secretary of the Company with effect from 13 April 2023.

APPOINTMENT OF EXECUTIVE DIRECTORS

The board (the “**Board**”) of directors (“**Directors**”, each a “**Director**”) of Kintor Pharmaceutical Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) hereby announces that Dr. Qun LU (“**Dr. Lu**”) and Dr. Xiang NI (“**Dr. Ni**”), who are respectively the existing chief technology officer (“**CTO**”) and chief medical officer (“**CMO**”) of the Company, have been appointed as executive Directors with effect from 14 April 2023.

The biographical details of Dr. Lu and Dr. Ni are set out below:

Dr. Lu, aged 57, joined the Group in May 2021 and is currently the CTO of the Group, primarily responsible for chemistry, manufacturing and control (“**CMC**”) including drug analysis, formulation development and the production. Dr. Lu has over 20 years

of experience in biopharmaceutical industry with proven track record of successfully leading the CMC development of pharmaceutical dosage forms from discovery through commercialisation at various pharmaceutical corporations including Pfizer, Merck and Celgene Corp./Bristol Myers Squibb (the “BMS”). Prior to joining the Group, Dr. Lu was an executive director at Celgene Corp./BMS in New Jersey from 2013 to 2019 and from 2019 to 2021 respectively, where she focused on defining and delivering integrated CMC development strategies and outcomes for innovative medicines. She also served as a member of the board of directors of International Consortium for Innovation and Quality in Pharmaceutical Development until 2019. Dr. Lu received her bachelor’s degree in Chemistry from Peking University in 1987 and completed her Ph.D. in Physical Chemistry at Arizona State University in 1995. Dr. Lu carried out post-doctoral studies in Pharmaceutics at the University of Wisconsin – Madison from 1996 to 1997.

Dr. Ni, aged 54, joined the Group in March 2023 and is currently the CMO of the Group, primarily responsible for the coordination, management and supervision of the medical work of the Group. Dr. Ni has dedicated to the international biopharmaceutical field for more than 20 years, with extensive experience and expertise in the clinical development of new drugs, pharmacovigilance and clinical quality. Prior to joining the Group, Dr. Ni worked in pharmaceutical companies in the United States and China, like AstraZeneca and several innovative biopharma and biotechnology companies like Akesobio and Aquater. Dr. Ni has facilitated the approval of several global new drug applications (NDAs) and new drug clinical trials (INDs). He also has extensive experience working with global regulatory agencies. Dr. Ni received his bachelor’s degree in Medicine from Southeast University School of Medicine in China in 1992 and his Ph.D. degree from School of Medicine, Temple University in the United States in 2000.

Each of Dr. Lu and Dr. Ni has entered into a service contract with the Company for an initial term of three years commencing on 14 April 2023, subject to retirement by rotation and re-election at the general meeting of the Company pursuant to the articles of association of the Company. The remuneration packages of Directors are determined by reference to the Company’s performance and profitability, the prevailing market conditions and the performance or contribution of each Director. Under their contracts of employment, Dr. Lu is entitled to an annual salary which together with other benefits amounting to approximately RMB2.8 million and is eligible to receive a performance-related discretionary bonus. As at the date of this announcement, Dr. Lu is interested in 0.8 million restricted share units (representing 0.8 million underlying shares of the Company) under the employee incentive scheme of the Company. Dr. Ni is entitled to an annual salary which together with other benefits amounting to approximately USD0.51 million and is eligible to receive a performance-related discretionary bonus. Pursuant to their service contracts, Dr. Lu and Dr. Ni will not receive any emoluments from the Company for their appointments as executive Directors.

Save as disclosed above, to the best knowledge and belief of the Board and having made all reasonable enquiries, as at the date of this announcement, each of Dr. Lu and Dr. Ni (i) has not held any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas during the last three years, (ii) does not have any relationship with any director, senior management or substantial or controlling shareholder of the Company, (iii) does not hold any other positions in the Company or any of its subsidiaries and (iv) does not have, and is not deemed to have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571) of the Law of Hong Kong. Save as disclosed above, the Board is not aware of any other matters in relation to the appointment of Dr. Lu and Dr. Ni as executive Directors that need to be brought to the attention of the shareholders of the Company, nor is there any other information that should be disclosed by the Company pursuant to Rule 13.51(2)(h) to (v) of the Rules (the “**Listing Rules**”) governing the Listing of Securities on the Stock Exchange (the “**Stock Exchange**”).

The Board would like to express its warm welcome to Dr. Lu and Dr. Ni to the Board. The Board believes that Dr. Lu and Dr. Ni’s relevant experience in research and development will further enhance the profession of the Board, thereby benefiting the overall corporate governance of the Company.

APPOINTMENT OF CHIEF FINANCIAL OFFICER

The Board announces that Mr. Ming Ming CHEUNG (“**Mr. Cheung**”), the vice president of investment and overseas business of the Group, has been appointed as the chief financial officer (the “**CFO**”) of the Company with effect from 14 April 2023. Mr. Cheung will be primarily responsible for the financial planning, investment, international commerce, internal control, investor relations and public relations of the Group. In light of Mr. Cheung’s new role as the CFO, Mr. Cheung has ceased to act as the vice president of investment and overseas business with effect from 14 April 2023.

The biographical details of Mr. Cheung are set out below:

Mr. Cheung, aged 46, joined the Group in September 2021 as the vice president of investment and overseas business of the Group. Mr. Cheung has over 15 years’ of work experience in the capital market. Prior to joining the Group, he was Head of Leveraged & Acquisition Finance of Haitong International Securities Group Limited, a company listed on the Stock Exchange (stock code: 0665). He was in charge of leveraged acquisition finance and equity fund investments respectively. Mr. Cheung also worked in ING Bank Hong Kong Branch for over 5 years. He was responsible for corporate client coverage and merger and acquisition financial advisory. Mr. Cheung obtained his bachelor’s degree in Biochemistry from the Hong Kong University of Science and Technology in 1999 and Master of Philosophy in Bioinformatics from Medical School, the University of Hong Kong in 2002.

RESIGNATION OF EXECUTIVE DIRECTOR, CHIEF FINANCIAL OFFICER AND JOINT COMPANY SECRETARY

Ms. Yan LU (“**Ms. Lu**”) tendered her resignation as the executive Director, the CFO, and the joint company secretary of the Company with effect from 13 April 2023 to pursue her personal endeavours. Following the resignation of Ms. Lu, Mr. Wai Chiu WONG, the remaining joint company secretary of the Company, will act as the sole company secretary of the Company.

Ms. Lu has confirmed that she has no disagreement with the Board, and there is no other matter relating to her resignation that needs to be brought to the attention of the Stock Exchange and the shareholders of the Company.

The Board would like to take this opportunity to welcome Mr. Cheung to his new role and express its sincere gratitude to Ms. Lu for her remarkable contributions to the Group.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Chairman, Executive Director and Chief Executive Officer

Hong Kong, 14 April 2023

As of the date of this announcement, the executive Directors are Dr. Youzhi Tong, Dr. Qun Lu and Dr. Xiang Ni; the non-executive Directors are Mr. Weipeng Gao, Ms. Geqi Wei and Mr. Chengwei Liu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*